Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Arthur A. LevinDirector | Avidity Biosciences | Open-market sale10b5-1 plan | 01/21 | 01/23 | 1,758 sh | $72.45 | $127,367.1 | −9.6% |
Avidity Biosciences | Open-market sale10b5-1 plan | 01/21 | 01/23 | 4,542 sh2 trades | $72.45avg. | $329,067.9 | −7.1% | |
Avidity Biosciences | Open-market sale10b5-1 plan | 01/21 | 01/23 | 14,387 sh2 trades | $72.45avg. | $1,042,338.15 | −5.1% | |
Avidity Biosciences | Open-market sale10b5-1 plan | 01/21 | 01/23 | 4,895 sh2 trades | $72.45avg. | $354,642.75 | −13.4% | |
Avidity Biosciences | Open-market sale10b5-1 plan | 01/21 | 01/23 | 6,534 sh2 trades | $72.45avg. | $473,388.3 | −7.1% | |
Avidity Biosciences | Open-market sale10b5-1 plan | 01/21 | 01/23 | 2,929 sh2 trades | $72.45avg. | $212,206.05 | −2.5% | |
Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 1,974 sh | $72.23 | $142,582.02 | −3.0% | |
John B. MoriartyChief Legal Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 2,374 sh | $72.23 | $171,474.02 | −3.1% |
Sarah BoycePresident and CEO | Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 8,576 sh | $72.23 | $619,444.48 | −2.9% |
Steven George HughesChief Medical Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 2,373 sh | $72.23 | $171,401.79 | −6.1% |
W. Michael FlanaganChief Scientific Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 2,373 sh | $72.23 | $171,401.79 | −2.5% |
Teresa McCarthyChief Human Resources Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 1,965 sh | $72.23 | $141,931.95 | −1.7% |
Charles Calderaro IIIChief Technical Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 01/07 | 01/09 | 3,727 sh | $72.23 | $269,201.21 | −7.0% |
Steven George HughesChief Medical Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/10/22 | 25/10/24 | 2,209 sh | $47.54 | $105,015.86 | −5.4% |
Teresa McCarthyChief Human Resources Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/10/15 | 25/10/17 | 20,000 sh | $50.15 | $1,003,000 | −17.1% |
Eric MosbrookerChief Commercial Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/10/03 | 25/10/07 | 6,562 sh | $45.38 | $297,783.56 | −10.7% |
Steven George HughesChief Medical Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/09/22 | 25/09/23 | 2,208 sh | $40.58 | $89,600.64 | −5.4% |
Steven George HughesChief Medical Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/09/15 | 25/09/17 | 1,542 sh | $45.41 | $70,022.22 | −3.8% |
Teresa McCarthyChief Human Resources Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/09/15 | 25/09/17 | 15,000 sh | $41.41 | $621,150 | −13.4% |
W. Michael FlanaganChief Scientific Officer | Avidity Biosciences | Open-market sale10b5-1 plan | 25/09/11 | 25/09/12 | 20,000 sh | $38.94 | $778,800 | −20.0% |